Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 30, 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of specific personnel transactions rather than a financial performance report.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document details a specific increase in the notional allocation of American Depositary Shares (ADSs) within the GSK 401K plan following a revaluation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on September 27, 2013.
- Transaction Price: The ADS price was $50.48 per share.
- Involved Parties: The transaction involved Dr. M. Slaoui (Director) and Dr. K. Slaoui (Connected Person).
- Allocation Details: Dr. M. Slaoui received no additional ADSs, while Dr. K. Slaoui received an increase of 4 ADSs.
- Plan Context: The transaction relates to the revaluation of the cash element of the notional investment held within the GSK 401K plan.